Plexx in the Black

Possibly unaware of a recent nightclub incident, Roche just put a valuation of 60 million up front for PLX-5568: the ph1 Raf inhibitor.  Likely from the aza-indole genre.

PLX-5568

Plexxikon’s Ph1 in healthy volunteers underway with plans for and pain and PKD. They’re not advertising the target, but my guess is c-fms. We’ve been following their earlier cFms / cKkit double-stuff, and its likely they found a group to tune out the Kit, maybe something like: WO/2008/080015

still no partner…

Plexxikon’s cFms/cKit stuff:

Some of Plexxicon’s latest cKit / cFms stuff has published, and surprise-surprise its got their ‘scaffold’. The choice of where to tag on amines suggests the following motif:

This week: US20070032519
Last week: WO/2007/013896
Last year: WO/2006/009797

PLX4032: burried in here?

So you know that kinase your working on. Yah, yah that one. Turns out that Plexxikon has compounds that inhibit it too. No, really. Between their two most recent applications to publish: WO/2007/002325, and WO/2007/002433 they claim <10 uM inhibition on no less then 36 kinases (+ n isoforms) with 22 authors. It’s an impressive body of matter, if pyrrolopyridines are your thing, and 1200+ pages of patent apps don’t scare you, check it out.